• (-)-JQ1 Workflows for BET Control Rigor

  2026-08-15

  (-)-JQ1 is an inactive JQ1 stereoisomer designed to separate BET-dependent biology from vehicle, cytotoxicity, and assay-specific effects. This guide shows how to deploy it in BRD4 target gene modulation, epigenetics research, and translational cancer workflows alongside active (+)-JQ1.

• BX795: PDK1 Inhibitor for Signaling Studies

  2026-08-14

  BX795 combines potent PDK1 inhibition with activity against TBK1 and IKKε, making it useful for separating kinase-driven cancer phenotypes from innate immune and autophagy responses. This guide translates that profile into practical biochemical, cellular, HBV-related, and troubleshooting workflows.

• RIPostC, Ketone Bodies, and Ferroptosis in Stroke

  2026-08-14

  This ACS Chemical Neuroscience study identifies ketone body metabolism as a mechanistic link between remote ischemic postconditioning (RIPostC) and neuroprotection after ischemic stroke. In rat and neuronal-cell models, RIPostC-associated ketone bodies were linked to improved energy status, reduced iron-dependent lipid peroxidation, preservation of GPX4, and suppression of ACSL4.

• Itraconazole: From Biofilm Phenotype to Assay Design

  2026-08-13

  Itraconazole is a triazole antifungal agent whose experimental value extends beyond growth inhibition. This article translates PP2A–autophagy findings in Candida albicans into practical assay decisions involving biofilm state, CYP3A4 interactions, formulation, and mechanistic interpretation.

• CKI 7 Dihydrochloride: Assay Strategy

  2026-08-13

  Explore how CKI 7 dihydrochloride can serve as a mechanistic Casein kinase 1 inhibitor in pathway-focused experiments. This assay-centered guide connects CK1 perturbation with Wnt, circadian, apoptosis, and cancer research while carefully distinguishing it from the MAPK10–KRT16 metastasis mechanism.

• Hoechst 33258 for Tumor pH and DNA Analysis

  2026-08-12

  Hoechst 33258 converts tumor-treatment experiments into interpretable DNA-content, nuclear-morphology, and cell-cycle readouts across live-cell microscopy and flow cytometry. This article shows how to pair a bis-benzimide DNA stain with pH-disrupting chemo-immunotherapy models while avoiding common errors caused by dye efflux, photobleaching, and treatment-induced debris.

• Lysosomal β-Galactosidase Staining Kit in HNSCC

  2026-08-12

  Learn how the Lysosomal β-Galactosidase Staining Kit can clarify senescence-associated lysosomal activity in cisplatin-resistant HNSCC models. This guide focuses on assay interpretation, controls, and the distinction between a useful senescence phenotype readout and proof of mechanism.

• How Kinase Inhibitors Accelerate p38α Dephosphorylation

  2026-08-11

  The reference study shows that selected kinase inhibitors can do more than occupy the p38α ATP site: they can also expose the activation-loop phospho-threonine to WIP1, accelerating kinase dephosphorylation. This structural and biochemical insight suggests a route to designing inhibitors that combine direct catalytic blockade with phosphatase-assisted pathway shutdown.

• Sodium Ascorbate for ROS Cancer Cell Assays

  2026-08-10

  Sodium Ascorbate provides a practical oxidative-stress perturbation for glioblastoma multiforme research, cancer cell proliferation inhibition, and invasion assays. This workflow combines fresh solvent preparation, time-resolved ROS and necrosis measurements, and a cautious extension into tumor–immune biomarker studies without treating exploratory links as clinical evidence.

• Doxycycline hyclate for MMP and BBB Research

  2026-08-09

  Doxycycline hyclate provides a practical way to probe MMP-2/MMP-9-driven blood–brain barrier failure while connecting molecular, histological, and behavioral readouts. This workflow also shows how the same research-grade compound can support carefully separated antiviral and antimalarial investigations.

• Solanesol (B8776): Practical Workflow Guide

  2026-08-08

  Solanesol is a hydrophobic polyisoprenoid alcohol for biochemical workflows that require controlled handling of a membrane-associated research compound. This guide covers DMSO preparation, storage, dilution, and quality control, while defining why it should not be used in water- or ethanol-based systems or for diagnostic and medical applications.

• In Vitro Embryonic Dormancy Through mTOR Inhibition

  2026-08-07

  Iyer and colleagues present detailed, reversible in vitro protocols for placing mouse blastocysts, human blastoids, and mouse or human pluripotent stem cells into a diapause-like dormant state through pharmacological mTOR inhibition. The approach replaces invasive surgery-based models with scalable culture workflows that can be used to study dormancy mechanisms, developmental competence, and the timing of early embryonic development.

• HotStart™ 2X Green qPCR Master Mix: Data Integrity for qPCR

  2026-08-07

  Explore how HotStart™ 2X Green qPCR Master Mix (SKU K1070) addresses real laboratory challenges in gene expression and cell viability workflows. This scenario-driven guide delivers practical, evidence-based strategies for consistent, sensitive qPCR results, focusing on data-backed advantages in specificity, reproducibility, and workflow efficiency.

• Azilsartan Medoxomil Monopotassium: Next-Gen ARB for Transla

  2026-08-06

  This thought-leadership article explores the advanced mechanistic underpinnings, experimental best practices, and translational opportunities presented by Azilsartan medoxomil monopotassium (TAK 491). Bridging recent clinical evidence and emerging laboratory workflows, it offers strategic guidance for cardiovascular disease researchers leveraging this next-generation, high-affinity AT1 receptor antagonist.

• EphA2 as a Synthetic Lethal Target in MYC-Driven TNBC: Chemo

  2026-08-06

  This study introduces a chemogenetic screening platform to uncover synthetic lethal vulnerabilities in MYC-driven triple-negative breast cancer (TNBC), identifying EphA2 inhibition as a potent strategy. The findings reveal that targeting EphA2 triggers MYC-selective apoptosis, independent of p53 status, and impedes tumor growth in vivo, informing new therapeutic approaches for aggressive TNBC.

453 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page